Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment (PREDAPP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03452618 |
Recruitment Status :
Recruiting
First Posted : March 2, 2018
Last Update Posted : September 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Amyotrophic Lateral Sclerosis | Diagnostic Test: diagnosis variables | Not Applicable |
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease. The diagnosis of this diaphragmatic dysfunction in the ALS subject is done all too often on the occasion of a hospitalization for acute respiratory insufficiency, which aggravates then the prognosis of the patients.
The presence of these factors at diagnosis will allow more surveillance to detect early diaphragmatic insufficiency and establish a NIV (Non Invasive Ventilation), the only therapeutic measure definitely improving the quality of life and survival of patients. A clinical score will be established to determine the risk of early Non Invasive Ventilation (NIV) equipment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The study compare the diagnostic's variables in patients who received NIV one year after diagnosis and those who did not. |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment in Patients With Amyotrophic Lateral Sclerosis |
Actual Study Start Date : | December 14, 2017 |
Estimated Primary Completion Date : | December 14, 2021 |
Estimated Study Completion Date : | December 14, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: patients with a NIV equipment
Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
|
Diagnostic Test: diagnosis variables
The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears The diagnostic variable are :
|
Active Comparator: patients without a NIV equipment
Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
|
Diagnostic Test: diagnosis variables
The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears The diagnostic variable are :
|
- Early Surgical Clinical Score [ Time Frame: One year after diagnostic ]
An Early Surgical Clinical Score will be established taking into account the independent variables correlated to diagnosis at early fitting.
Clinical Variables :
- Presence of bulbar involvement or not
- Time from onset of first symptoms to diagnosis
- Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) score : The Amyotrophic Lateral Sclerosis Functional Ra ting Scale (ALSFRS) is an instrument for evaluating the functional status of patients with Amyotrophic Lateral Sclerosis. It can be used to monitor functional change in a patient over time.
- Presence of another underlying respiratory disease
Functional Variables :
- Time from onset of first symptoms to diagnosis of ALS
- Presence of another underlying respiratory pathology
- Forced Vital Capacity (FVC) measurement
- PaCO2 measurement
- Measure Sniff Nasal Inspiratory Pressure (SNIP)
- Measurement of diaphragmatic activity on ultrasound
- Parameters of the Polysomnography (PSG)
- Sensitivity, specificity, negative and positive predictive values [ Time Frame: One year after the diagnostic ]Sensitivity, specificity, negative and positive predictive values of the diaphragmatic ultrasound (fraction of shortening and diaphragmatic stroke) compared to the SNIP test and for the values of PSG (Polysomnography) compared to SNIP test
- Percentage of decrease [ Time Frame: One year after the diagnostic ]% decrease in shortening fraction and diaphragmatic stroke between two quarterly reevaluations correlated with early fitting and % decrease in FVC, SNIP test et Pimax
- Slope of FVC decline [ Time Frame: One year after the diagnostic ]Slope of FVC decline before and after NIV implementation and slope of decline of shortening fraction and diaphragmatic stroke before and after NIV
- Quality of life score [ Time Frame: One year after the diagnostic ]Quality of life score by the Severe Respiratory Insufficiency (SRI) questionnaire :before and after implementation of the NIV The Severe Respiratory Insufficiency (SRI) Questionnaire: a specific measure of health-related quality of life in patients receiving home mechanical ventilation.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of amyotrophic lateral sclerosis just performed,
- Patient who do not have the criteria for fitting by NIV and who have a Vital capacity ≥ 70% of theoretical values
Exclusion Criteria:
- Patient under court bail/ guardianship
- Lack of consent for participation in the study
- Presence of criteria for setting up the NIV for diagnosis according to the HAS (HealthCare Analytics Summit) 2006 recommendations
- Vital capacity <70% of the theoretical values
- Patient under Continuous Positive Pressure (CPP) or NIV for a respiratory pathology other

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03452618
Contact: Marion Dupuis, MD | 5 67 77 16 91 ext 33 | dupuis.m@chu-toulouse.fr | |
Contact: Isabelle Olivier, PhD | 5 61 77 70 51 ext 33 | olivier.i@chu-toulouse.fr |
France | |
University Hospital Toulouse | Recruiting |
Toulouse, France, 31052 | |
Contact: Marion Dupuis, MD 5 67 77 16 91 ext 33 dupuis.m@chu-toulouse.fr |
Principal Investigator: | Marion Dupuis, MD | University Hospital, Toulouse |
Responsible Party: | University Hospital, Toulouse |
ClinicalTrials.gov Identifier: | NCT03452618 |
Other Study ID Numbers: |
RC31/17/0201 2017-A02202-51 ( Other Identifier: ID-RCB ) |
First Posted: | March 2, 2018 Key Record Dates |
Last Update Posted: | September 1, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
diagnostic criteria |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases |
Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases |